Wall Street analysts expect that Prothena Corporation PLC (NASDAQ:PRTA) will announce sales of $8.52 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Prothena Corporation PLC’s earnings. The lowest sales estimate is $330,000.00 and the highest is $30.23 million. Prothena Corporation PLC posted sales of $330,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 2,481.8%. The business is scheduled to issue its next earnings report on Tuesday, August 1st.

On average, analysts expect that Prothena Corporation PLC will report full-year sales of $8.52 million for the current fiscal year, with estimates ranging from $4.00 million to $31.19 million. For the next financial year, analysts anticipate that the company will post sales of $42.16 million per share, with estimates ranging from $1.56 million to $101.20 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Prothena Corporation PLC.

Prothena Corporation PLC (NASDAQ:PRTA) last issued its earnings results on Tuesday, May 9th. The biotechnology company reported ($0.99) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.32) by $0.33. Prothena Corporation PLC had a negative net margin of 16,012.49% and a negative return on equity of 39.67%. The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.26 million. During the same period last year, the business posted ($0.81) EPS. Prothena Corporation PLC’s revenue was down 3.7% on a year-over-year basis.

A number of research analysts have weighed in on PRTA shares. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Prothena Corporation PLC in a research note on Wednesday, March 22nd. Instinet started coverage on shares of Prothena Corporation PLC in a research note on Wednesday, March 1st. They issued a “buy” rating and a $87.00 target price on the stock. Nomura started coverage on shares of Prothena Corporation PLC in a research note on Wednesday, March 1st. They issued a “buy” rating on the stock. Zacks Investment Research upgraded shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $59.00 target price on the stock in a research note on Tuesday, April 18th. Finally, BTIG Research started coverage on shares of Prothena Corporation PLC in a research note on Friday, May 19th. They issued a “buy” rating and a $80.00 target price on the stock. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $75.50.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/8-52-million-in-sales-expected-for-prothena-corporation-plc-prta-this-quarter/1384824.html.

In related news, insider Karin L. Walker sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, April 17th. The shares were sold at an average price of $52.25, for a total transaction of $261,250.00. Following the sale, the insider now directly owns 3,000 shares in the company, valued at approximately $156,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dennis J. Selkoe sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, April 3rd. The shares were sold at an average price of $55.86, for a total transaction of $195,510.00. Following the sale, the director now owns 6,345 shares in the company, valued at $354,431.70. The disclosure for this sale can be found here. Corporate insiders own 3.10% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new stake in shares of Prothena Corporation PLC during the first quarter worth approximately $167,000. Stifel Financial Corp acquired a new stake in shares of Prothena Corporation PLC during the first quarter worth approximately $224,000. Karp Capital Management Corp acquired a new stake in shares of Prothena Corporation PLC during the first quarter worth approximately $243,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Prothena Corporation PLC during the first quarter worth approximately $273,000. Finally, Principal Financial Group Inc. boosted its stake in shares of Prothena Corporation PLC by 1.2% in the first quarter. Principal Financial Group Inc. now owns 6,528 shares of the biotechnology company’s stock worth $364,000 after buying an additional 77 shares during the last quarter.

Shares of Prothena Corporation PLC (PRTA) traded up 1.25% during midday trading on Thursday, reaching $57.32. 115,213 shares of the company traded hands. The firm’s market capitalization is $2.18 billion. Prothena Corporation PLC has a 12-month low of $33.53 and a 12-month high of $68.18. The company has a 50-day moving average of $53.15 and a 200 day moving average of $52.62.

Prothena Corporation PLC Company Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Get a free copy of the Zacks research report on Prothena Corporation PLC (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.